

Product Data Sheet

Dostarlimab

Cat. No.:	HY-P99345	
CAS No.:	2022215-59-2	
Target:	PD-1/PD-L1	
Pathway:	Immunology/Inflammation	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY			
Description	Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC ₅₀ s of 1.8 and 1.5 nM, respectively ^[1] .		
IC ₅₀ & Target	IC50: 1.5 nM (PD-L2/ PD-1), 1.8 nM (PD-L1/ PD-1) ^[1]		
In Vitro	Dostarlimab (10-10000 ng/mL) binds to native PD-1 receptor expressed on human and cynomolgus monkey CD3 ⁺ T cells in a dose-dependent manner ^[1] . Dostarlimab (0-375 nM; 48 h) increases IL-2 production with an EC ₅₀ of approximately 1 nM in a human CD4 ⁺ T-cell MLR assay, increases IL-2 production with an EC ₅₀ of approximately 0.1 nM in staphylococcal enterotoxin B (SEB)-stimulated PBMCs, enhances interferon (IFN)-γ release with an EC ₅₀ of approximately 0.5 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Dostarlimab (200 µg/mou MCE has not independen Animal Model: Dosage: Administration: Result:	use; i.p.; twice weekly for 35 days) shows antitumor activity in humanized mouse models ^[1] . tly confirmed the accuracy of these methods. They are for reference only. Humanized NOG-EXL mice, A549 and MDA-MB-436 tumor model ^[1] 200 μg/mouse Intraperitoneal injection; twice weekly for 35 days Resulted in great inhibition of tumor growth in an A549 lung cancer model (tumor growth inhibition [TGI] of 62% at termination). The antitumor activity was associated with a reduction in tumor-associated regulatory T cells and a trend toward increased tumor- infiltrating CD8 ⁺ T cells. Inhibited tumor growth of MDA-MB-436 breast cancer model (TGI of 53%).	

REFERENCES

[1]. Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA